Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy Evaluation of TROP2 ADC Therapy in Patients With Advanced/Metastatic NSCLC Resistant to EGFR-TKIs: A Comparative Imaging Study of ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT

NCT07685197 is registered in ClinicalTrials.gov with Zhou Chengzhi as lead sponsor.

NCT NCT07685197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07685197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy Evaluation of TROP2 ADC Therapy in Patients With Advanced/Metastatic NSCLC Resistant to EGFR-TKIs: A Comparative Imaging Study of ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT
Lead sponsor
Zhou Chengzhi
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
July 31, 2028
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, egfr-tki-resistant non-small cell lung cancer, nsclc, pet/ct imaging, trop2